Ipsen (EPA:IPN) said today that Teijin Pharma Ltd. won approval from the Japanese Ministry of Health, Labor and Welfare for Ipsen’s Somatuline as a therapy for gastroenteropancreatic neuroendocrine tumors. The subcutaneous drug was approved in Japan in 2012 for the treatment of acromegaly and pituitary gigantism. Get the full story at our sister site, Drug Delivery Business News.
7 medtech stories we missed this week: May 26, 2017
From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Merck inks exclusive licensing agreement for Alzheimer’s antibody Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. […]